Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	8.25B
Revenue (ttm)	5.72B
Net Income (ttm)	2.34B
Shares Out	n/a
EPS (ttm)	29.96
PE Ratio	3.53
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,047
Average Volume	7,183
Open	91.20
Previous Close	90.96
Day's Range	90.73 - 104.13
52-Week Range	67.15 - 124.45
Beta	n/a
RSI	65.53
Earnings Date	Feb 10, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,246
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In 2024, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.